Answers are grounded in this paper and cite their sources.
Wacker Chemie, the German specialty chemicals firm, has opened a new facility for making messenger RNA (mRNA)–based active ingredients for medicines such as vaccines and cancer drugs at its site in Halle, Germany. The facility, which cost over $100 million, has four mRNA production lines. It more than triples Wacker's production capacity at Halle, to over 200 million vaccine doses annually. The company plans to open a biotech center in Munich later this year.
No takes yet. Share an insight, caveat, or question.
Alex Scott (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: